Bendamustine Plus Rituximab Effective for Relapsed, Refractory Mantle Cell Lymphoma

Bendamustine plus rituximab is an effective therapy with manageable toxicity in patients with relapsed/refractory mantle cell lymphoma.
Bendamustine plus rituximab is an effective therapy with manageable toxicity in patients with relapsed/refractory mantle cell lymphoma.

Bendamustine plus rituximab is an effective therapy with manageable toxicity in patients with relapsed/refractory mantle cell lymphoma, a recent study published in the journal Annals of Hematology has shown.1

For the multicenter, open-label, single-arm, phase 2 trial, researchers enrolled 45 patients with relapsed/refractory non-blastoid mantle cell lymphoma, of which 82% had stage 4 disease. All patients received bendamustine 90 mg/m2 on days 1 and 2 plus rituximab 375 mg/m2 on day 1 for 6 28-day cycles.

Results showed that 82% of patients achieved a response, 40% achieved a complete response, and 42% achieved a partial one. Researchers also found that 75% of patients achieved a complete metabolic response.

The study demonstrated a 1-year progression-free survival rate and 3-year overall survival rate of 67% and 55%, respectively.

In regard to safety, the most common nonhematologic adverse events were nausea, fatigue, decreased appetite, constipation, diarrhea, vomiting, and decreased weight. Grade 3 to 4 neutropenia and lymphopenia occurred in 44% and 89% of patients, respectively.

Mantle cell lymphoma is an uncommon form of non-Hodgkin lymphoma that comprises only approximately 5% of lymphomas. Although not fast-growing, it can be a challenging disease to treat. Newer treatments such as ibrutinib, however, may improve long-term survival.2

Reference

  1. Czuczman MS, Goy A, Lamonica D, Munteanu MC, van der Jagt RH. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol. 2015;94(12):2025-2032.
  2. Types of non-Hodgkin lymphoma. American Cancer Society website. http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkin-lymphoma. Last revised March 11, 2015. Accessed November 4, 2015.
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs